A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)
Condition(s)
Lung Cancer (NSCLC), Pancreatic Cancer
Molecular Target(s)
HER2, HER3
Drug Classification(s)
Molecular Targeted Therapy
Agents(s)
any treatments that use the protein folate receptor alpha or FRĪ± to work
Phase(s)
I/II
Mechanism of Action
Zenocutuzumab, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3
Purpose
n/a
Location
Mary Crowley Cancer Research - Medical City Dallas
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.
7777 Forest Lane,
Building C-707
Dallas, TX 75230
972.566.3000